日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway

DNMT2-m5C-ACLY轴通过组蛋白乙酰化介导的Notch通路促进肝细胞癌对乐伐替尼的耐药性

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202515931
Yang, Shiguang; Li, Jie; Mao, Shengwei; Zhao, Xuhui; Liu, Douwaner; Chen, Jiafeng; Fu, Jialu; Bu, Yichao; Wu, Xiaoling; Liu, Shaoqing; Yu, Qifeng; Dong, Qiongzhu; Tang, Zheng; Fang, Yuan; Shi, Yinghong
m6A/m5C/m7G
肿瘤
表观遗传
肿瘤免疫
Notch
信号转导
乙酰化
细胞生物学
发表日期：2026
文献求助 收藏

MSMO1 promotes chemotherapy resistance through modulation of T-MAS metabolism via PERK/elF2α/ATF4/CHOP pathway

MSMO1通过PERK/eIF2α/ATF4/CHOP通路调控T-MAS代谢，从而促进化疗耐药。

期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2026.114790
Ren, Hengyu; Wang, Xuliren; Shao, Zhibo; Xiong, Min; Chi, Weiru; Sang, Yuting; Zhang, Qi; Wang, Zehao; Liu, Douwaner; Zhang, Liyi; Chen, Ming; Zhu, Han; Xue, Jingyan; Xiu, Bingqiu; Chi, Yayun; Wu, Jiong
SMO
信号转导
HOP
CHOP
多发性硬化症
MAPK/ERK
代谢
ATF4
PERK
发表日期：2026
文献求助 收藏

XBP1s Mediates Cross-resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer.

XBP1s介导乳腺癌中CDK4/6抑制剂联合内分泌治疗的交叉耐药性。

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202409588
Sang Yuting, Liu Shiyang, Zhou Xujie, Chi Weiru, Xiong Min, Chen Ming, Ren Hengyu, Liu Douwaner, Zhang Liyi, Xue Jingyan, Chi Yayun, Wu Jiong
乳腺癌
免疫/内分泌
CDK4
XBP1
发表日期：2025
文献求助 收藏

PPARG Activation of Fatty Acid Metabolism Drives Resistance to Anti-HER2 Therapies in HER2-Positive Breast Cancer

PPARG激活脂肪酸代谢驱动HER2阳性乳腺癌对HER2抑制剂的耐药性

期刊:International Journal of Biological Sciences
影响因子:10
doi:10.7150/ijbs.99275
Xiong, Min; Liu, Douwaner; Wang, Xuliren; Ren, Hengyu; Chi, Weiru; Xiu, Bingqiu; Zhang, Qi; Zhang, Jiayu; Zhang, Liyi; Wang, Zehao; Chen, Ming; Xue, Jingyan; Chi, Yayun; Wu, Jiong
肿瘤
HER2
肿瘤免疫
乳腺癌
代谢
PARG
PPARG
发表日期：2025
文献求助 收藏

JCAD-Derived from Plasma Exosomes: Promoting Tumor Cell Progression and Predicting Poor Outcomes in Breast Cancer

源自血浆外泌体的JCAD：促进肿瘤细胞进展并预测乳腺癌不良预后

期刊:International Journal of Biological Sciences
影响因子:10
doi:10.7150/ijbs.107763
Liu, Douwaner; Xiong, Min; Chen, Xiaoting; Wang, Xuliren; Sang, Yuting; Liu, Shiyang; Zhang, Liyi; Chi, Weiru; Ren, Hengyu; Xiu, Bingqiu; Zhang, Qi; Chi, Yayun; Wu, Jiong; Xue, Jingyan
外泌体
肿瘤
肿瘤免疫
乳腺癌
细胞生物学
肿瘤细胞
发表日期：2025
文献求助 收藏

Assessing neoadjuvant treatment response through serum human epidermal growth factor receptor 2 (HER2) dynamics

通过血清人表皮生长因子受体2 (HER2) 动态变化评估新辅助治疗反应

期刊:Gland Surgery
影响因子:1.6
doi:10.21037/gs-24-432
Wang, Xuliren; Xiong, Min; Shao, Zhibo; Xiu, Bingqiu; Zhang, Qi; Liu, Douwaner; Chi, Weiru; Zhang, Liyi; Chen, Ming; Ren, Hengyu; Shao, Zhi-Ming; Chen, Jiajian; Wu, Jiong
信号转导
HER2
发表日期：2025
文献求助 收藏

Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort

基于TP53状态的多基因panel体细胞突变对接受新辅助治疗的中国HER2阳性患者预后的影响：一项单中心回顾性队列研究

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.6955
Xiong, Min; Wang, Xuliren; Liu, Douwaner; Xiu, Bingqiu; Zhang, Qi; Chi, Weiru; Goh, Chih Wan; Zhang, Liyi; Chen, Ming; Ren, Hengyu; Shao, Zhi-Ming; Yang, Benlong; Wu, Jiong
细胞生物学
P53
HER2
发表日期：2024
文献求助 收藏